Description
Pharmacological action
Slenfig is an drug for the treatment of central action obesity. The mechanism of action is due to selective inhibition of serotonin reuptake of norepinephrine and, to a lesser extent, of dopamine. This medication accelerates the onset and prolong satiety, which leads to a decrease in food consumption. It increases energy expenditure by stimulating thermogenesis mediated by activation of beta3-adrenergic receptors. Acts on both sides of the balance of energy and helps reduce body weight.
Slenfig and its metabolites did not release monoamines, and they are not MAO inhibitors, have no affinity for serotonergic, adrenergic, dopaminergic, muscarinic, histamine, benzodiazepine and NMDA receptors.
Pharmacokinetics
After oral administration Slenfig is rapidly absorbed from the gastrointestinal tract. Almost completely metabolized in the liver, with the participation of cytochrome isozymes CYP3A4, as well as by hydroxylation and conjugation to form inactive metabolites. Cmax of Slenfig is achieved in 1.2 h. This medicine is quickly and widely distributed in tissues. The plasma protein binding is 97%. T1/2 is 1.1 h. Slenfig derived primarily by the kidneys as inactive metabolites.
Why is Slenfig prescribed?
As part of the supporting complex treatment of patients with overweight in alimentary obesity with a body mass index of 30 kg / m2 or more, with alimentary obesity with a body mass index of 27 kg / m2 or more in the presence of other risk factors due to overweight, including diabetes mellitus type 2, or hyperlipidemia.
Dosage and administration
The initial dose is 10 mg / day. With lack of effectiveness when used in this dose (weight loss less than 2 kg for 4 weeks) and if tolerated the dose can be increased to 15 mg / day.
If no effect when Slenfig used in doses of 15 mg / day (weight loss less than 2 kg per 4 weeks), this drug should be discontinued.
In patients not adequately responding to treatment, that is who within 3 months can not reach the level of 5% weight loss from baseline, the duration of use this medication should not exceed 3 months.
The course of treatment is not more than 1 year since no data on efficacy and safety of longer use.
Do not use Slenfig, if after made weight loss achieved in the course of further therapy, the patient again adds to the weight of 3 kg or more.
More: https://www.sdrugs.com/?c=drug&s=slenfig
Reviews
There are no reviews yet.